Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

MedAdvisor Gelecekteki Büyüme

Future kriter kontrolleri 4/6

MedAdvisor kazanç ve gelirin sırasıyla yıllık 67.9% ve 13.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 68% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 18.8% olacağı tahmin edilmektedir.

Anahtar bilgiler

67.9%

Kazanç büyüme oranı

68.0%

EPS büyüme oranı

Healthcare Services kazanç büyümesi	21.3%
Gelir büyüme oranı	13.8%
Gelecekteki özkaynak getirisi	18.8%
Analist kapsamı	Low
Son güncelleme	30 Aug 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now

Nov 09

Is MedAdvisor (ASX:MDR) A Risky Investment?

Oct 11

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Mar 08

MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain

Feb 10

What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?

Jan 18

The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares

Dec 22

What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?

Dec 18

Here's Why We're Not Too Worried About MedAdvisor's (ASX:MDR) Cash Burn Situation

Nov 22

Kazanç ve Gelir Büyüme Tahminleri

ASX:MDR - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (AUD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2027	186	14	17	22	2
6/30/2026	163	10	14	17	3
6/30/2025	143	2	6	9	3
6/30/2024	122	1	3	5	N/A
3/31/2024	116	-4	-2	0	N/A
12/31/2023	109	-9	-7	-6	N/A
9/30/2023	104	-10	-4	-4	N/A
6/30/2023	98	-11	-2	-1	N/A
3/31/2023	96	-8	7	7	N/A
12/31/2022	93	-5	16	16	N/A
9/30/2022	80	-11	8	8	N/A
6/30/2022	68	-17	-1	0	N/A
3/31/2022	66	-16	-6	-5	N/A
12/31/2021	64	-14	-11	-11	N/A
9/30/2021	52	-14	-12	-12	N/A
6/30/2021	39	-14	-13	-13	N/A
3/31/2021	28	-13	-10	-9	N/A
12/31/2020	18	-12	-6	-6	N/A
9/30/2020	14	-11	-8	-7	N/A
6/30/2020	10	-10	-9	-9	N/A
3/31/2020	9	-9	-9	-8	N/A
12/31/2019	9	-9	-8	-8	N/A
9/30/2019	9	-8	-8	-7	N/A
6/30/2019	8	-8	-7	-7	N/A
3/31/2019	8	-7	-6	-6	N/A
12/31/2018	7	-7	-6	-5	N/A
9/30/2018	7	-6	-5	-4	N/A
6/30/2018	7	-4	-4	-3	N/A
3/31/2018	6	-4	N/A	-3	N/A
12/31/2017	6	-4	N/A	-3	N/A
9/30/2017	5	-4	N/A	-3	N/A
6/30/2017	4	-3	N/A	-2	N/A
3/31/2017	3	-4	N/A	-3	N/A
12/31/2016	2	-4	N/A	-3	N/A
9/30/2016	2	-4	N/A	-3	N/A
6/30/2016	1	-3	N/A	-3	N/A
3/31/2016	1	-2	N/A	-2	N/A
12/31/2015	2	-1	N/A	-1	N/A
9/30/2015	2	-1	N/A	-1	N/A
6/30/2015	2	-1	N/A	0	N/A
6/30/2014	1	-1	N/A	-1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MDR 'nin tahmini kazanç büyümesi (yıllık 67.9% ) tasarruf oranının ( 2.4% ) üzerindedir.

Kazançlar ve Piyasa: MDR şirketinin kazançlarının (yıllık 67.9% ) Australian pazarından (yıllık 12.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: MDR şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: MDR şirketinin gelirinin (yıllık 13.8% ) Australian pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MDR şirketinin gelirinin (yıllık 13.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MDR 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 18.8 %).

MedAdvisor Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Forecast breakeven date pushed back to 2025

Price target increased by 13% to AU$0.51

Consensus EPS estimates upgraded to AU$0.0033 loss

Forecast breakeven date moved forward to 2025

Consensus EPS estimates fall by 11%, revenue upgraded

Forecast breakeven date pushed back to 2026

Recent updates

MedAdvisor Limited Announces the Resignation of Anthony Tassone as Non-Executive Director

MedAdvisor Limited, Annual General Meeting, Nov 14, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

MedAdvisor Limited Announces Board Resignations

Forecast breakeven date pushed back to 2025

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Price target increased by 13% to AU$0.51

Consensus EPS estimates upgraded to AU$0.0033 loss

Forecast breakeven date moved forward to 2025

Consensus EPS estimates fall by 11%, revenue upgraded

Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S

Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?

Forecast breakeven date pushed back to 2026

New minor risk - Profitability

Now 24% overvalued after recent price rise

Consensus estimates of losses per share improve by 33%

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Non-Executive Director recently bought AU$1.2m worth of stock

MedAdvisor Limited, Annual General Meeting, Nov 28, 2023

Consensus estimates of losses per share improve by 32%

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 50%

MedAdvisor Limited Announces Board Changes

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Consensus EPS estimates fall by 80%, revenue upgraded

First half 2023 earnings released: EPS: AU$0.009 (vs AU$0.02 loss in 1H 2022)

Price target increased to AU$0.40

MedAdvisor Limited Provides Revenue Guidance for the First Half of the Fiscal Year 2023

MedAdvisor Limited Appoints Kevin Hutchinson as Director

Less than half of directors are independent

MedAdvisor Limited to Report Q1, 2023 Results on Oct 28, 2022

MedAdvisor Limited Announces Board Changes

MedAdvisor Limited, Annual General Meeting, Nov 30, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

MedAdvisor Limited (ASX:MDR) entered a binding agreement to acquire GuildLink Pty Ltd from Guild Group Holdings Limited for AUD 8 million.

MedAdvisor Limited Announces Executive Changes

MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt

MedAdvisor Limited Announces Change of Managing Director

Price target decreased to AU$0.40

No longer forecast to breakeven

Less than half of directors are independent

MedAdvisor Limited Announces Retirement of Robert Read as CEO

Consensus forecasts updated

MedAdvisor Limited Announces Board Changes

MedAdvisor Limited to Report First Half, 2022 Results on Feb 25, 2022

MedAdvisor Limited Appoints Raeann Grossman to the Board as A Non-Executive Director

Independent Non-Executive Director Peter Bennetto has left the company

Non-Executive Director recently sold AU$2.5m worth of stock

Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now

Is MedAdvisor (ASX:MDR) A Risky Investment?

Less than half of directors are independent

Full year 2021 earnings released

Non-Executive Director has left the company

MedAdvisor Limited announced that it has received AUD 5.25 million in funding

New 90-day low: AU$0.34

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

First half 2021 earnings released: AU$0.029 loss per share (vs AU$0.024 loss in 1H 2020)

MedAdvisor Limited to Report First Half, 2021 Results on Feb 25, 2021

MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain

What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?

New 90-day low: AU$0.34

Non-Executive Chairman of the Board recently bought AU$70k worth of stock

The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares

MedAdvisor Limited Signs an Additional One-Year Deal with A Major Global Pharmaceutical Company

What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?

New 90-day low: AU$0.36

Here's Why We're Not Too Worried About MedAdvisor's (ASX:MDR) Cash Burn Situation

New 90-day low: AU$0.39

MedAdvisor Limited Extends Health Programs in the US